Plasma histidine as biomarker for recurrent atrial fibrillation after catheter ablation

1 September 2025 (08:35 - 08:45)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Hongxuan Xu

Beijing (China)

4 More presentations in this session

Presentation thumbnail

LVA ablation following the PVI strategy showed better outcomes in diabetic patients with wide LVA compared to narrow LVA: A Sub-Analysis of the SUPPRESS-AF Trial

Doctor T. Ozaki (Osaka, JP)

Abstract Slides

Presentation thumbnail

Pulmonary vein reconduction is common in patients undergoing re-ablation after first-time pulsed field ablation for atrial fibrillation

Doctor C. Alhede (Copenhagen, DK)

Abstract Slides

Presentation thumbnail

Balancing stroke and bleeding risks: the impact of stopping anticoagulation after aAF ablation - a systematic review and meta-analysis

Doctor S. Koolaji (Stevenage, GB)

Abstract Slides

Presentation thumbnail

Left atrial appendage isolation in catheter ablation of atrial fibrillation: an updated systematic review and meta-analysis.

Doctor M. Nassar (Tanta, EG)

Abstract Slides

Access the full session

Session thumbnail

New insights in catheter ablation of atrial fibrillation

The Event

Event poster

ESC Congress 2025

1 September 2025 08:35 CET

You may be interested in

Congress Presentation

Predictive value of biomarker dynamics for atrial fibrillation recurrence after pulmonary vein isolation: a prospective cohort study

Congress Presentation

Associations of 1- and 3-methylhistidine with long-term risk of acute myocardial infarction and mortality

Congress Presentation

Pulsed field ablation systems differentially affect cardiac biomarkers in atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources